drugset / Trial / NCT00127881
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.
Timeline
- Start
- 2005-07
- Primary completion
- 2014-02
- Completion
- —
Outcome
Outcome not reported
Stopped: “New sponsor, other treatments available”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanolimumab | Monoclonal antibody | — | — |